The glutamatergic system is the major excitatory neurotransmitter system in the CNS. Glutamate receptors, and in particular N-methyl-D-aspartate (NMDA) receptors, have been proposed as mediators of many common neuropsychiatric phenotypes including cognition, psychosis, and degeneration. We have reconstructed the genomic structure of all five genes encoding NMDA receptors in silico. We screened each for sequence variation and estimated the allele frequencies of all detected SNPs in pooled samples of 184 UK Caucasian schizophrenics and 184 UK Caucasian blood donor controls. Only a single non-synonymous polymorphism was found indicating extreme selection pressure. The rarity of non-synonymous changes suggests that such variants are unlikely to make a common contribution to common phenotypes. We found a further 26 polymorphisms within exonic or adjacent intronic sequences. The minor alleles of most of these have a relatively high frequency (63% above 0.2). These SNPs will therefore be suitable for studying neuropsychiatric phenotypes that are putatively related to NMDA dysfunction. Pooled analysis provided no support for association between any of the GRIN genes and schizophrenia.
Introduction
The glutamatergic system is the major excitatory neurotransmitter system in the CNS. Glutamatergic transmission is mediated by receptor families that are classed ionotropic (iGluRs) and metabotropic (mGluRs). iGluRs are ligand-gated ion channels, which can in turn be sub-classified into the following groups based upon their ligand binding properties: N-methyl D-aspartate receptors (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors (AMPA), kainate (KA) and more recently delta. The majority of iGluRs are thought to be tetrameric or pentameric heteromultimers although the stoichiometry and precise composition of native receptors is at present unknown. 1 In addition to a multiplicity of genes, the diversity of iGluRs is increased by the potential for numerous sub-unit combinations of heteromultimers, by alternative splicing, and by RNA editing. transmission, these include neuronal migration, proliferation and excitability, synapse formation, stability and plasticity, and long term potentiation. [4] [5] [6] Because of these wide-ranging functions, altered glutamatergic neurotransmission has been implicated in many different CNS processes, physiological and pathological. These include learning and learning disability, memory, epilepsy, CNS recovery after trauma or ischaemia, neurodegenerative diseases, schizophrenia, affective disorder, and alcohol dependence. [6] [7] [8] [9] While more than 30 glutamatergic related cDNAs have been cloned in humans, the genomic structure of most has not been determined experimentally. This has obviously been an obstacle to molecular genetic tests of the glutamate hypotheses of the neuropsychiatric disorders mentioned above.
All glutamatergic related genes are good candidates for several neuropsychiatric disorders, but regionselective knock out studies in animals suggest that NMDA sub-units have probably the strongest a priori case for several phenotypes including learning and memory. 7, 8 Moreover, reduced expression of GRIN1 leads to behavioural abnormalities in mice that are similar to those observed in pharmacologically induced models of schizophrenia. 9 We have therefore targeted NMDA receptors as a priority for molecular genetic analysis. Five genes encoding NMDA sub-units have been identified in humans. NMDAR1 sub-units are encoded by GRIN1 and are believed to be common to all native NMDA receptors. 10 NMDA receptors are also thought to contain one or more NMDAR2 subunits from the family of NMDAR2A-D proteins, which are encoded by GRIN2A-D respectively. To facilitate candidate gene studies of NMDA receptors, we have reconstructed in silico the genomic structure of the 4 GRIN2 genes to complement the known structure of GRIN1, and subjected all the genes to mutation analysis using denaturing high performance liquid chromatography (DHPLC) and sequencing.
Materials and methods

Genomic structure and PCR
The genomic sequence of GRIN1 was previously reported 11 and is available (Acc No: Z32772; Z32773; Z32774). However, the annotation is inaccurate and the sequences specified as exons do not include either 5Ј or 3Ј UTRs. The genomic structure for GRIN1 including both the 5Ј and 3Ј UTRs was determined as described below. For GRIN2A-D we identified genomic clones by aligning each of their respective reference cDNA sequences with the genomic sequence data deposited in the 'non-redundant' and 'high-throughput sequencing' GenBank databases using BasicBLAST search 12 (http://www.ncbi.nlm.nih.gov/blast/blast.cgi). BLAST2 sequences 13 (http://www.ncbi.nlm.nih.gov/blast/bl2seq/ bl2.html) was then used to perform a gapped alignment between each cDNA and its corresponding genomic clone in order to determine its intron/exon structure. Genomic clones were only selected if they mapped to the same region as the gene and if each exon had at least 95% homology with the reference cDNA sequence. The derived genomic sequences were used to design primers using Primer3 (http://www-genome. wi.mit.edu/cgi-bin/primer/primer3Fwww.cgi). In order not to compromise the sensitivity of mutation screening, large exons were amplified using sets of amplimeres of no more than 600 bp that overlapped by no less than 50 bp. All PCRs were performed on MJ thermocyclers in a volume of 24 l containing 40 ng of genomic DNA, 10 pmol of each primer, 100 M dNTPs, and 0.5 units of Hotstar Taq Polymerase (Quiagen, UK) with a standard touchdown protocol previously described.
14 Genomic regions that proved particularly difficult to amplify due to their high GC content were amplified in a volume of 50 l using a GC-Rich PCR kit (Roche) using reaction and cycling conditions according to the manufacturer's instructions. Details of the primer sequences and PCR conditions can be obtained from our web site (http://psychmed.uwcm. ac.uk/psychosis/ publications/nmda.html).
Mutation detection
Mutation detection was performed by screening PCR products by DHPLC as described elsewhere.
14 To achieve maximum sensitivity, DHPLC analysis was performed at a minimum of two temperatures determined by DHPLCMelt software. In previous analyses in our laboratory, this protocol had a sensitivity of 100%. 15 
Molecular Psychiatry
Because we were concerned that reagents in the GCRich kit might alter the melting characteristics of DNA, the optimal DHPLC conditions for fragments amplified using this method were determined empirically as described elsewhere. 16 Where DHPLC analysis suggested that a subject was heterozygous, the PCR products from that individual were sequenced to determine the nature of the polymorphism using the Big Dye Terminator Cycle Sequencing Kit (Perkin Elmer Applied Biosystems, Cheshire, UK) as described by the manufacturer. All variants were confirmed by allele specific primer extension using SNaPshot chemistry (Perkin Elmer Applied Biosystems) using PCR products from a homozygote and a putative heterozygote as template. The allele frequency of each polymorphism was estimated in 184 UK Caucasian blood donors and 184 UK Caucasian schizophrenics by an accurate method of pooled genotyping based upon HPLC analysis of primer extension products 17 or by SNaPshot assay. The latter method has in our hands proved equally as accurate as the HPLC method (manuscript in preparation).
Subjects
All subjects used in this study were unrelated Caucasians born in the UK or Ireland. All cases met the DSM-IV 18 criteria for schizophrenia with diagnosis being determined using OPCRIT version 3.31 19 following a semi-structured interview, SCAN or PSE, 20, 21 and examination of case notes. The sample for mutation screening consisted of 14 unrelated cases who also had at least one first degree relative who suffered from schizophrenia and were selected randomly from families ascertained for linkage analysis. Allele frequencies were estimated in DNA pools constructed from 184 controls and 184 cases meeting DSM-IV criteria for schizophrenia. Local Research Ethics Committee approval was obtained, and subjects gave written informed consent to participate. Control individuals were group matched to cases for age, sex, and ethnicity from more than 1400 blood donors recruited from the local branch of the National Blood Transfusion Service (Wales).
Results
cDNA and genomic structure
According to the published data, GRIN1 has 21 exons.
11 Exons 1 and 21 were reported to span 258 and 186 bp respectively but this does not include 1093 bases of 5Ј UTR and 1227 bases of 3Ј UTR. With the inclusion of UTR sequences, we conclude that exons 1 and 21 actually span 1351 and 1344 bases respectively. We were unable to retrieve genomic clones corresponding to the terminal 484 bases of the 3Ј UTR of GRIN1 and therefore cannot exclude the possibility that there are further 3Ј exons. Sequence alignment of cDNA and genomic clones revealed that all GRIN2 genes have 13 exons (Table 1) . A similar conclusion regarding the structure of GRIN2B was recently reported by Ohtsuki et al. 
Mutation analysis
In order to perform DHPLC analysis of each gene we designed 109 PCR fragments. We could not amplify eight of these fragments, and we were therefore unable to screen these mutations. These fragments were all in GRIN2 genes and are indicated in Table 1 .
We have screened a total of 32 440 bp of genomic sequence of which 24 201 bp was exonic, 17 374 bp was coding, 1516 and 4838 bp were 5Ј UTR and 3Ј UTR respectively, and 8712 bp was flanking intronic sequence ( Table 2) . We found a total of 27 polymorphisms in the five NMDA receptor genes all of which have been deposited in HGBASE (http://hgbase. interactiva.de/). Ten of these were intronic, 17 were exonic of which 10 were within coding sequence. The only non-synonymous polymorphism was found in exon 6 of GRIN2C (1656GA;V490I). The details of each polymorphism together with allele frequencies in con- Table 3 . As part of a comprehensive analysis of the glutamatergic system, we propose to fully report all association data on more than 100 related SNPs in a single publication. In the interim, complete allele frequency data are available at our website (http://psychmed.uwcm.ac.uk/psychosis/publications/ nmda.html) but we note here that none of the alleles even displayed a trend (P Ͻ0.1) for association with schizophrenia. This included the GRIN2B 122CϾG polymorphism which was previously reported to be associated with schizophrenia in a Japanese sample.
22
In our sample the estimated allele frequencies for the least common allele were 0.43 and 0.44 (P = 0.99) in the controls and affecteds respectively. Based upon the mutation data, we have calculated the number of variant sites normalised for the number of chromosomes and base pairs screened 23 (). We have ) and for non-synonymous changes is 1.5 × 10 −5 (⌸ = 5.5 × 10
−6
). The values of and ⌸ for the coding sequences of each gene are given in Table 2 .
Discussion
All GRIN2 subtypes have a fairly conserved genomic structure of 13 exons, 12 of which contain coding sequence. This is in marked contrast to NMDAR1, which has been shown to consist of 21 exons. 11 We were able to design primers for most of the genomic sequence corresponding to GRIN cDNAs, but were unable to obtain specific PCR amplification for eight fragments (Table 1) , despite designing three different sets of primers and also attempting nested PCR. Possible explanations include pseudogenes, errors present in 'working draft' genomic clone sequences, or difficult secondary structure. Whatever the explanation, as a consequence, we have failed to screen 1920 bases (or 7.35%) of the genomic sequence corresponding to GRIN cDNA.
Our data reveal that the sequences of GRIN genes are well conserved. Based upon other data, 23, 24 for Europeans has been estimated at around 5 × 10 −4 in both coding and perigenic non-coding sequences. This compares with our estimate of for GRIN receptors of 2.1 × 10 −4 . This may in part reflect reduced diversity in our screening population, which is UK Caucasian. However, the effect of this is likely to be small as there is no reason to regard UK Caucasians as an isolated population. A second explanation may be that our mutation detection protocol is less sensitive than that used by the other groups. However, evaluation of DHPLC in our laboratory 15, 16 suggests this is not so. Thus, the third explanation is most likely correct, that is, GRIN genes are under strong selection pressure.
In keeping with this explanation, the most dramatic difference in diversity from published values was that for non-synonymous changes. Cargill and colleagues 23 found for non-synonymous SNPs approximately equal to that for synonymous SNPs while ⌸ for nonsynonymous SNPs was around two thirds that of synonymous. In contrast, we find that for non-synonymous SNPs in GRIN receptors is almost 10-fold less than for synonymous SNPs, while ⌸ is 40-fold less. Others who have recently studied individual members of the GRIN family have also found a low rate of nonsynonymous SNPs. 22, 25 For example when the GRIN1 gene was screened for mutations in 142 chromosomes from the Caucasian population, Rice and colleagues 25 found no non-synonymous changes and only two synonymous changes. A third synonymous change was found by genotyping a further 72 Caucasian chromosomes. For comparison with our data, we have re-calculated the coding sequence diversity values for Caucasian subjects in that study. 25 For synonymous changes, = 1.2 × 10 −4 and ⌸ = 2.8 × 10 −4 , for non-synonymous changes, both and ⌸ are zero. The results are therefore similar to our own analysis of NMDA genes. This implies that NMDA receptors are under particularly strong selection pressure to maintain conserved amino acid sequences. This is reflected in the high degree of amino acid sequence homology between human and mouse, with homology rates of 99%, 95%, 97%, 89% and 89% for NMDAR1 and NMDAR2A-D respectively. Perhaps this is not surprising given their pivotal role in so many neurophysiological processes.
The design of this study was powered upon the widely held (but unproven) common-disease commonpolymorphism hypothesis. Thus the number of subjects subjected to mutation analysis (chromosomes = 28) gives power of just less than 0.8 to detect polymorphisms with a minor allele frequency of 0.05, and power of 0.95 to detect polymorphisms with a minor allele frequency of 0.1. With regard to the full range of putative NMDA related disorders, we would point out that the use of schizophrenic probands for mutation screening only reduces power to detect relevant variants if the susceptibility alleles for these disorders are protective against schizophrenia, leading to under-representation in our screening set. As far as we are aware, there is no reduction in the prevalence of any common neuropsychiatric disorders in schizophrenic probands and therefore this caveat is unlikely to apply.
Our finding of only a single non-synonymous conservative polymorphism (VϾI) in GRIN genes suggests that the common-disease common-polymorphism hypothesis is unlikely to be applicable to GRIN receptors, at least with regard to variants that change sequence structure, and more particularly with regard to schizophrenia. However, our study does not exclude the possibility that there are rare non-synonymous SNPs in GRIN genes that cumulatively contribute to a small proportion of common neuropsychiatric phenotypes. If the rare allele hypothesis is correct, generic programmes of SNP identification in subjects unselected by phenotype are not likely to detect the relevant susceptibility alleles.
While non-synonymous polymorphisms in GRIN genes do not appear to make a common contribution to common phenotypes, we did find 27 polymorphisms within GRIN exonic or adjacent intronic sequences. With the increase in the number of SNPs available on databases, one question that arises is whether there is any point in individual groups continuing to pursue studies of this nature. For the time being at least, we believe that it is. Only around one third of the SNPs we report were previously lodged in public databases, and without validation and allele frequencies, the SNPs in databases are of limited value. 26 We have validated and determined allele frequencies of all our SNPs. Given their location and the relatively high allele frequency of most of the minor alleles (63% above 0.2), these SNPs will be suitable for molecular screening of GRIN receptors. 26 Moreover while they are not obviously functional, we cannot exclude the possi-bility that they might alter transcriptional efficiency, mRNA processing, editing, stability and translational efficiency. Thus, the SNPs we report in this paper will be of general interest to groups studying a range of neuropsychiatric interest.
With regard to schizophrenia specifically, our data provide no support for the hypothesis that DNA variation in genes encoding NMDA related proteins contribute to susceptibility to schizophrenia, given that none of the 27 SNPs provided even suggestive (P Յ0.1) evidence for association (http://psychmed.uwcm.ac. uk/psychosis/publications/nmda.html). There are three main caveats. Our case-control sample does not have power to exclude very small genetic effects from the polymorphisms we did detect. Thus, assuming effect sizes OR = 1.5, we have power of 0.8 to detect trends for association at our specified cut-off point (␣ = 0.1) with alleles with a frequency between 0.25-0.7, but power of only 0.5 for susceptibility alleles with a frequency of 0.1. The second is that very rare schizophrenia susceptibility alleles may not be detected by our screening set. It should be noted that the estimates of power for detecting polymorphisms of given frequencies refer to frequencies in the schizophrenic population, not the general population. Our screening sample is drawn from families with at least two affected individuals and therefore, under an oligo or polygenic model, is likely to be even more strongly enriched for schizophrenia susceptibility alleles. Therefore our power estimate of 0.8 will actually be maintained for detecting schizophrenia susceptibility alleles with even lower frequencies in the general population than we have estimated above. It is very likely therefore that provided the sum of the frequencies of all susceptibility alleles in GRIN genes is ෂ0.05, our study should have detected at least one of them. Clearly, until all susceptibility alleles at a locus are known, their number, frequencies, and the total contribution of that locus to disease susceptibility cannot be known either. It follows then that no locus can be fully excluded from contributing to a disease. However, recent modelling provides reassurance for studies such as our own. 27 Providing the cumulative frequency of susceptibility alleles at a locus is not small (Ͻ0.01), a few alleles are predicted to account for a high proportion of the total frequency of susceptibility alleles at that locus. 27 The third caveat is that none of the GRIN cDNAs is guaranteed in GenBank to be full length, nor is experimental evidence concerning the genomic sequences of their promoters and other important regulatory elements available. Accordingly, we have been unable as yet to screen sequences involved in regulating the expression of NMDA subunits.
